Skip to main content

Table 1 Clinical characteristics of the patients in this study

From: Impact on change in serum beta 2 microglobulin by combination therapy of peritoneal dialysis and hemodialysis: a 12-month preliminary observational study

Age (years)

56.4 ± 12.9

Laboratory data

 

Male, n (%)

10/11 (90.9)

Hemoglobin (g/dL)

10.0 ± 1.5

Body mass index (kg/m2)

25.3 ± 2.6

Serum albumin (g/dL)

3.1 ± 0.4

PD treatment period (year)

3.4 ± 1.3

Serum blood urea nitrogen (mg/dL)

58.0 ± 22.5

Etiology of renal insufficiency

Diabetes mellitus (7)

Serum creatinine (mg/dL)

15.1 ± 4.6

Glomerulonephritis (2)

Serum sodium (mEq/L)

134.1 ± 2.6

Polycystic kidney disease (1)

Serum potassium (mEq/L)

4.0 ± 0.5

Renal sclerosis (1)

Serum calcium (mg/dL)

4.0 ± 0.6

Urine volume (mL/day)

100 (0–1050)

Serum phosphorus (mg/dL)

6.7 ± 2.3

Renal Kt/V urea

0.01 ± 0.01

Intact parathyroid hormone (pg/mL)

239.2 ± 99.5

Renal CCr (mL/min)

4.7 ± 5.5

C-reactive protein (mg/dL)

0.8 ± 1.5

Peritoneal dialysis treatment

 

Serum beta 2 microglobulin (mg/L)

32.7(30.7–51.2)

Total PD fluid volume (L/day)

9.5 ± 2.2

  

Weekly Kt/V

1.6 ± 0.3

  

Hemodialysis treatment conditions

HD sessions per week

1

Dialyzer type (n)

Ia

10

Treatment time per HD session (hours)

4

 

IIa

1

Blood flow rate (mL/min)

200 (200–250)

Membrane area of the dialyzers (m2)

2.4 ± 0.2

 
  1. Data are shown as the mean ± SD or median (min–max). PD peritoneal dialysis, HD hemodialysis